ello, everyone, and how are you today? We are just fine, thank you, especially since a charming snowfall has dusted the Pharmalot campus. Nothing like a pretty wintry scene, is there? Alas, the time has come, though, to focus on the matters at hand. This calls, of course, for a cup of stimulation — cherry chocolate decadence is our choice, for those tracking our variety — and we invite you to join us. Remember, no prescription is required. Meanwhile, here are some items of interest. Hope your day is smashing and do keep in touch …

Teva Pharmaceuticals (TEVA) released its long-awaited restructuring. Here are key details: 14,000 layoffs globally, or 25 percent of its workforce; close or sell a “significant” number of its 80 or so manufacturing plants; reprice or discontinue some generics; close or sell a “significant” number of R&D facilities and review all R&D programs; end dividends on ordinary shares and suspend annual bonuses this year. The moves are expected to save $3 billion by the end of 2019.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • “Aging” is a disease well known to the FDA. They’ve suffered from it for a long time. If I went back to grad school I would get a doctorate in archeology, as there is a wealth of fossils dwelling at the agency.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.